Introduction
Although most attention has traditionally focused on the stomach, diabetes can affect the entire gastrointestinal tract. The term diabetic enteropathy refers to all the gastrointestinal complications of diabetes. Gastrointestinal involvement may be asymptomatic or manifest as symptoms (i.e. dysphagia, heartburn, nausea and vomiting, abdominal pain, constipation, diarrhea and fecal incontinence). These manifestations may affect quality of life, impair nutrition, and affect glycemic control.
Epidemiology
Studies in selected patient groups, often from tertiary referral centers, suggest that gastrointestinal symptoms are common in diabetes mellitus [1, 2] ; however, these studies are prone to selection and other biases, which are avoided by studies conducted among people with diabetes in the community, where the prevalence of gastrointestinal symptoms is either not different, or only slightly higher than people without diabetes. Thus, in the Rochester Diabetic Neuropathy Study, only 1% of patients had symptoms of gastroparesis and only 0.6% had nocturnal diarrhea [3] . In another study from Olmsted County, Minnesota, the prevalence of gastrointestinal symptoms (i.e. nausea and/or vomiting, dyspepsia, heartburn, irritable bowel syndrome, constipation and fecal incontinence) was not signifi cantly different between individuals with either type 1 (T1DM) or type 2 diabetes mellitus (T2DM) and age -matched controls [4] ; however, people with T2DM and men with T1DM used laxatives more frequently than in controls. Moreover, that study and a Finnish populationbased study reported that people with T1DM had a lower prevalence of heartburn [5] .
In contrast to these studies, a study from Australia found that the prevalence of several upper and lower gastrointestinal symptoms was higher in 423 patients with predominantly (95%) T2DM than in controls [6] . Taken together, these data suggest that gastrointestinal manifestations are not uncommon among patients with diabetes presenting for care. In the general population, however, the prevalence of gastrointestinal manifestations is not substantially higher among people with diabetes and matched controls, perhaps partly because the prevalence of gastrointestinal symptoms, mostly attributable to functional gastrointestinal disorders (e.g. irritable bowel syndrome), among people without diabetes in the community is relatively high, and approaches 20%. In Olmsted County, Minnesota, the ageadjusted incidence per 100,000 person -years of defi nite gastroparesis for the years 1996 -2006 was 2.4 (95% confi dence interval [CI] 1.2 -3.8) for men and 9.8 (95% CI 7.5 -12.1) for women. The age -adjusted prevalence of defi nite gastroparesis per 100 000 persons on January 1, 2007, was 9.6 (95% CI 1.8 -17.4) for men and 37.8 (95% CI 23.3 -52.4) for women [7] .
Normal g astrointestinal m otor f unctions
Gastrointestinal motor function is primarily controlled by the intrinsic or enteric nervous system (i.e. the " little brain " in the digestive tract) and modulated by the extrinsic (i.e. parasympathetic and sympathetic) nervous system (Figure 46.1 ) [13] . While intrinsic and extrinsic controls are independent, the prevertebral ganglia integrate afferent impulses between the gut and the central nervous system and provide additional refl ex control of the abdominal viscera. The parasympathetic arm is excitatory to non -sphincteric muscle and inhibits sphincters. The sympathetic component has opposite effects. The enteric nervous system consists of 100 million neurons that are organized in distinct ganglionated plexi including the submucous plexus, which is primarily involved in absorption and secretion, and the myenteric plexus, which regulates motility. The interstitial cells of Cajal serve as pacemakers and also convey messages from nerve to smooth muscle. As with the somatic and autonomic nerves elsewhere, the gut ' s autonomic and enteric nervous system can be affected in diabetes. Derangements of the extrinsic nerves at any level may alter gastrointestinal motility and secretion [14] .
Gastrointestinal digestion and absorption require gastrointestinal motility, gastric and pancreatic secretion, and gastrointestinal hormonal release, which in turn, modulate motor, secretory and absorptive functions in the upper gut [15] . Traditionally, these processes are considered in three phases (cephalic, gastric and intestinal), which are integrated and overlap. Normally, liquids, particularly non -caloric liquids, empty rapidly from the stomach in a linear fashion. In contrast, gastric emptying of solids follows an exponential pattern. During the fi rst 45 minute postprandial period (i.e. the lag phase), the gastric antrum grinds Diabetic gastroparesis may cause severe symptoms and result in nutritional compromise, impaired glucose control and a poor quality of life, independently of other factors such as age, tobacco use, alcohol use or type of diabetes [8] . Studies of the natural history of gastroparesis have been limited by relatively small numbers of patients, potential referral bias or short follow -up periods. The data suggest that gastric emptying and its symptoms are generally stable during 12 years of followup or more [9] . In a study of 86 patients with diabetes who were followed for at least 9 years, gastroparesis was not associated with mortality after adjustment for other disorders [10] . Among patients with gastroparesis, overall survival was signifi cantly lower than the age -and sex -specifi c expected survival computed from the Minnesota white population [7] ; the most common causes of death were cardiovascular disease (24.6%), respiratory failure (23.2%), malignancy (15.9%), chronic renal failure in 11 (15.9%), cerebrovascular accident (10.1%) and other causes (10.1%).
Pathophysiology
Gastrointestinal dysmotility in diabetes is caused by extrinsic (i.e. sympathetic and parasympathetic) neural dysfunction, hyperglycemia and hormonal disturbances. More recently, a role for intrinsic (i.e. enteric) neuronal dysfunctions, resulting from loss of excitatory and inhibitory neurons and interstitial cells of Cajal, has also been implicated [11] . Neural dysfunction has been attributed to several mechanisms (e.g. oxidative stress) described below and detailed elsewhere [12] . 99m Tc, in patients with diabetes. At time 0 (i.e. fi rst image in each panel), the entire meal was in the stomach. Thereafter, the normal ranges for gastric emptying are 11 -39% at 1 hour, 40 -76% at 2 hours and 84 -98% at 4 hours.
Distention by bolus
hyperglycemia [11] . The effects of diabetes on neuronal morphology and functions are reversible. Insulin or pancreas transplantation improved glycemic control and the axonopathy affecting autonomic nerves in rats with diabetic autonomic neuropathy [19] . Insulin also restored expression of NOS and gastric emptying in animal models of diabetes while insulin and insulin -like growth factors prevented the loss of ICC in cultures [20, 21] . Because ICC do not express receptors for either hormone, these effects are perhaps mediated by smooth muscle secretion of stem cell factor, which is the most important growth factor for ICC rather than directly by insulin and insulin -like growth factors [11] . Overexpression of glial cell line -derived neurotrophic factor, a trophic factor for enteric neurons, in transgenic mice reversed hyperglycemia -induced apoptosis of enteric neurons, improved gastric emptying and intestinal transit [22] .
Pathophysiology of d iabetic e nteropathy in h umans

Gastric d ysfunctions
Neuropathy
Diabetes is associated with accelerated or delayed gastric emptying, increased and reduced gastric sensation, and impaired gastric accommodation ( Figure 46.4 ) . A vagal neuropathy can cause antral hypomotility and/or pylorospasm, which may delay gastric emptying [23] . The pathophysiology of rapid gastric emptying in diabetes is less well understood. Conceivably, impaired gastric accommodation resulting from a vagal neuropathy [24] may increase gastric pressure and thereby accelerate gastric emptying of liquids. However, the relationship between rapid gastric emptying and impaired gastric accommodation has not been substandistal small intestine exert feedback control of proximal small intestinal motility, a process known as the small intestinal brake. Chyme is transferred from the ileum to colon in intermittent boluses. On average, it takes 36 hours, with an upper limit of 65 hours, to transfer contents from the cecum to the rectum. Compared to the stomach and small intestine, colonic transit is relatively prolonged, permitting digestion of fi ber and absorption of water and electrolytes to be completed.
Pathophysiology of d iabetic e nteropathy: i nsights from a nimal s tudies
In animal models, extrinsic neural dysfunction has been primarily implicated to a loss of myelinated and unmyelinated fi bers without much neuronal loss [16, 17] . The loss of nerve fi bers is often multifocal, suggestive of ischemic injury. Within the enteric nervous system, reduced neuronal staining, and to a lesser extent neuronal loss, particularly inhibitory neurons expressing nitric oxide synthase (NOS) have been described in several animal models of diabetes [12] . In theory, this reduction in nitrergic inhibitory functions may contribute to impaired gastric accommodation and accelerated intestinal transit in diabetes. Reduced sympathetic inhibition may also contribute to accelerated intestinal transit. Because nitric oxide (NO) is a mediator of pyloric relaxation, loss of NOS may impair pyloric relaxation and thereby retard gastric emptying. Loss of intestinal cells of Cajal (ICC), documented in several animal models and case reports of diabetes, may also contribute to gut dysmotility [11, 18] .
Several mechanisms, including apoptosis, oxidative stress, advanced glycation end products and neuroimmune mechanisms may be responsible for neuronal loss and gut dysmotility [12] . The loss of ICC has been attributed to a reduction in hemeoxygenase (HO -1) and other protective mechanisms against glycemia, electrolyte imbalances caused by diabetic ketoacidosis (e.g. hypokalemia) and uremia may also aggravate impaired motor function in patients with diabetes. Iatrogenic gastroparesis may result from treatment with amylin or GLP -1 analogs.
Diabetic d iarrhea
It is useful to categorize the pathophysiology of diabetic diarrhea into conditions that are associated with malabsorption and those that are not ( Figure 46 .5 ). Involvement of sympathetic fi bers, which normally inhibit motility and facilitate absorption via α 2 -adrenergic receptors, can result in accelerated small intestinal transit and cause diarrhea [38] . Artifi cial sweeteners such as sorbitol may also contribute to diarrhea. Patients with rapid ileal transit may have bile acid malabsorption [39, 40] and deconjugated bile acids induce colonic secretion.
Features suggestive of malabsorption such as anemia, macrocytosis or steatorrhea should prompt consideration of bacterial overgrowth, small bowel mucosal disease or pancreatic insufficiency. Small intestinal dysmotility predisposes to bacterial overgrowth, which can cause bile salt deconjugation, fat malabsorption and diarrhea. Although T1DM is associated with celiac disease, most patients with celiac disease and T1DM in the community are asymptomatic [41] . Chronic pancreatic insuffi ciency may result from pancreatic atrophy, disruption of cholinergic enteropancreatic refl exes, or elevated serum hormonal levels of glucagon, somatostatin and pancreatic polypeptide, which reduce pancreatic enzyme secretion [42] . Nevertheless, the association between chronic pancreatic insuffi ciency and diabetes is uncommon. Moreover, because there is suffi cient pancreatic reserve, tiated. The relationship between vagal neuropathy and impaired post -prandial accommodation is unclear because accommodation may be preserved even in people with diabetes and vagal neuropathy [25] , perhaps refl ecting non -vagal adaptive mechanisms involving enteric neurons [26] . Some patients with diabetes and gastroparesis also have small intestinal dysmotility, more frequently characterized by reduced than by increased motility [27] . Small bowel dysmotility may also contribute to gastric stasis.
Hyperglycemia
Acute hyperglycemia delays gastric emptying in healthy subjects and in T1DM [28 -31] . These effects may be explained by hyperglycemia -induced suppression of antral motility and migrating motor activity, the so -called intestinal " housekeeper " [32 -34] . The effects of acute hyperglycemia on gastric emptying are modest. Indeed, even in T1DM, severe acute hyperglycemia (i.e. 16 -20 mmol/L vs 4 -8 mmol/L) prolonged the gastric emptying half -time by only 17 minutes from 124 to 141 minutes. Acute modulation of blood glucose within the physiologic postprandial range (4 -8 mmol/L) can also delay gastric emptying, to a lesser degree [31] . Cross -sectional studies suggest that higher glycated hemoglobin concentrations are associated with a higher prevalence of gastrointestinal symptoms and slower gastric emptying among people with diabetes in the community [6, 35] . While strict glycemic control improves neural, renal and retinal functions in diabetes, the impact on gastric emptying is unclear [36] . Indeed, in the only study that assessed this question, improved glycemic control did not improve gastric emptying 1 week later in 10 patients with T2DM [37] . In addition to hyper- may reveal esophageal peristaltic disturbances in patients with signifi cant dysphagia that is not explained by a structural lesion, it is unlikely to alter management, except for rare patients in whom another disorder, such as achalasia, is responsible for dysphagia. Because of the high prevalence of coronary atherosclerosis in diabetes, testing for coronary artery disease should be considered when necessary in patients with chest pain.
Dyspepsia and g astroparesis
Although gastroparesis refers to a syndrome characterized by symptoms of nausea, vomiting, early satiation after meals and impaired nutrition and objective evidence of markedly delayed gastric emptying, gastric retention may be asymptomatic [50] , perhaps because of the afferent dysfunction associated with vagal denervation [51] . Nausea and vomiting often occur in episodes lasting days to months or in cycles. Nausea and vomiting may be associated with impaired glycemic control and often cause hypoglycemia, perhaps because delivery of food into the small bowel for absorption is not suffi cient to match the effects of exogenous insulin. Consistent with the concept of a paralyzed stomach, the term gastroparesis should be restricted to patients with markedly delayed gastric emptying. When the delay in gastric emptying is not severe, the term diabetic dyspepsia is perhaps more appropriate. Dypepsia is characterized by one or more, generally postprandial, upper gastrointestinal symptoms, including bloating, post -prandial fullness and upper abdominal pain. Typically, vomiting is not severe but signifi cant weight loss secondary to reduced caloric intake is not unusual. In addition to delayed gastric emptying, impaired gastric accommodation and abnormal, either increased or decreased, gastric sensation may also contribute to symptoms in diabetes [52, 53] . Nonetheless, the distinction of dyspepsia from gastroparesis is challenging because there is no offi cial distinction between moderately and severely delayed gastric emptying. Perhaps, gastric emptying of less than 65% at 4 hours refl ects a signifi cant delay as it is often associated with nutritional consequences, the need for nutritional supplementation, jejunal feeding or gastric decompression [54] .
Patients with diabetic gastroparesis frequently have longstanding T1DM with other microvascular complications, including retinopathy, nephropathy, peripheral neuropathy and other forms of autonomic dysfunction. These can present as abnormal pupillary responses, anhidrosis, gustatory sweating, orthostatic hypotension, impotence, retrograde ejaculation and dysfunction of the urinary bladder) (Table 46 .1 ). In contrast, it has been suggested that rapid gastric emptying of liquids is a relatively early manifestation of T2DM [55 -59] . Clinicians have relied on these manifestations, and on certain symptoms, such as vomiting of undigested food eaten several hours previously and weight loss, and signs (e.g. a gastric succussion splash or features of an autonomic neuropathy) to predict delayed gastric emptying in patients with diabetes who present with upper and gastrointestinal symptoms. Several studies have shown, however, that symptoms are of limited utility for predicting delayed gastric emptying in diabetes only 10% of pancreatic function is suffi cient for normal digestion.
Fecal i ncontinence
Loose stools and anorectal dysfunctions contribute to fecal incontinence in diabetic diarrhea. Compared to continent people with diabetes and healthy controls, patients with diabetes and fecal incontinence have a higher threshold for rectal perception of balloon distention, a marker of reduced sensation [43, 44] . A sympathetic neuropathy may impair internal anal sphincter function and anal resting pressures while a pudendal neuropathy may result in reduced anal squeeze pressure.
Constipation
The mechanisms of constipation in diabetes have not been carefully studied and are poorly understood. Clinical observations suggest that, similar to idiopathic chronic constipation, both colonic dysmotility and anorectal dysfunctions, such as impaired anal sphincteric relaxation during defecation, may contribute to constipation in diabetes [45] . Patients with colonic dysmotility have an impaired colonic contractile response to a meal and delayed colonic transit [46] . Patients with reduced rectal sensation may not perceive the desire to defecate. Compared to euglycemia, acute hyperglyemia inhibits the colonic contractile response to gastric distention and proximal colonic contraction elicited by colonic distention in healthy subjects [47] . By contrast, acute hyperglycemia did not signifi cantly affect fasting or postprandial colonic tone, motility, compliance and sensation, or rectal compliance and sensation in healthy people [48] .
In addition to these factors, it is also important to consider the role of psychologic factors in the perception of gastrointestinal symptoms. Indeed, psychosomatic symptoms are significantly associated with the reporting of gastrointestinal tract symptoms [4] . Several medications have gastrointestinal side effects; for example, metformin can cause diarrhea while among other medications, verapamil and anticholinergic agents, can cause constipation.
Clinical m anifestations
Dysphagia and h eartburn
Esophageal dysmotility, typically characterized by impaired peristalsis with simultaneous contractions, is common, may cause dysphagia, and may be related to cardiovascular autonomic neuropathy in diabetic mellitus [49] . The amplitude of peristaltic contractions and basal lower esophageal sphincter pressures are generally normal. Symptoms of gastroesophageal refl ux are also common, particularly in patients with impaired gastric emptying who have vomiting. Rarely, recurrent vomiting may lead to Mallory -Weiss tears and bleeding.
Dysphagia and heartburn should prompt upper gastrointestinal endoscopy to exclude refl ux and other incidental mucosal diseases, such as candidiasis and neoplasms. While manometry disease and neoplasms, either of which can cause gastric outlet obstruction. Upper endoscopy may reveal gastric bezoars, which suggest antral hypomotility. Metabolic derangements, such as diabetic ketoacidosis or uremia, and medications, particularly opiates, calcium -channel blockers and anticholinergic agents, may contribute to dysmotility. Rarely, patients with gastroparesis present with retrosternal or epigastric pain and cardiac, biliary or pancreatic disease may be considered.
Barium X -rays of the small intestine or enterography with computed tomography should be considered only when the clinical features raise the possibility of small intestinal obstruction. Gastric emptying of solids should be quantifi ed by scintigraphy and antroduodenal manometry should be considered in selected circumstances. Measurement of pressure profi les in the stomach and small bowel can confi rm the motor disturbance and may facilitate the selection of patients for enteral feeding (Figure 46 .6 ). Patients with selective antral hypomotility may tolerate feeding delivered directly into the small bowel while those with a more generalized motility disorder may not.
Diarrhea and c onstipation
The term diabetic diarrhea was fi rst coined in 1936 by Bargen at the Mayo Clinic to describe unexplained diarrhea associated with severe diabetes [68] . Diabetic diarrhea is typically chronic, may be episodic and can be severe. Diarrhea can occur at any time but is often nocturnal and may be associated with anal incontinence, [60 -66] . Similarly, the type and duration of diabetes, glycated hemoglobin levels and extraintestinal complications were, in general, not useful for discriminating normal from delayed or rapid gastric emptying; however, signifi cant weight loss and a neuropathy were risk factors for delayed and rapid gastric emptying, respectively [67] . In patients with upper gastrointestinal symptoms, an upper gastrointestinal endoscopy is necessary to exclude peptic ulcer which may indicate internal anal sphincter dysfunction. Patients with diarrhea often have symptoms of delayed gastric emptying such as early satiety, nausea and vomiting.
Constipation may occur in isolation or alternate with episodes of diarrhea. Many physicians regard constipation to be synonymous with infrequent bowel movements. It is important to characterize symptoms because many people have misconceptions about normal bowel habits. For example, it is not necessary to have a bowel movement daily -the normal range varies from three bowel movements every week to three every day. Moreover, by constipation, patients refer to one or more of a variety of symptoms including infrequent stools, hard stools, excessive straining during defecation, a sense of anorectal blockage during defecation, the need for anal digitation during defecation and a sense of incomplete evacuation after defecation [69] . Some of these symptoms, such as a sense of anorectal blockage during defecation, may suggest disordered evacuation. A careful rectal examination during relaxation and straining is needed to exclude rectal mucosal lesions and to detect the presence of rectal prolapse, rectocele and disordered defecation. Normally, voluntary contraction is accompanied by upward and anterior motion of the palpating fi nger toward the umbilicus as the puborectalis contracts. Conversely, the puborectalis should relax and the perineum should descend (by 2 -4 cm) during simulated evacuation. The rectal examination may suggest features or defecatory disorders such as reduced or increased perineal descent and paradoxical contraction of puborectalis.
Abdominal p ain
Patients with diabetes are obviously susceptible to the usual causes of abdominal pain seen in the general population. There is an increased prevalence of gallstones because of altered gallbladder contractility and of mesenteric ischemia caused by generalized atherosclerosis; however, there is little evidence that altered gallbladder contractility per se (i.e. in the absence of gallstones) causes symptoms. Thoracolumbar radiculopathy may result in pain in a girdle -like distribution which does not cross the midline. Specifi c tests are indicated in the clinical features of pain suggest these disorders. It is essential to elicit a careful history.
Diagnostic t ests
Typically, diagnostic testing is primarily guided by symptom pattern and severity; however, because patients with delayed gastric emptying are often asymptomatic, gastric emptying assessments should also be considered in patients with unexplained hypoglycemia. After initial testing to identify disturbances of transit, more detailed testing with intraluminal techniques, such as manometry and/or a barostat, may be useful for characterizing motor dysfunctions and guiding therapy (Table 46. 2 ). Autonomic function testing is also useful [70] . Delayed gastric emptying can be documented by scintigraphy or the presence of a large amount of retained food in the stomach. Barium studies and scintigraphy using labeled liquid meals are of limited value for identifying dysmotility because the gastric emptying of liquids and semisolids (e.g. mashed potatoes) frequently is normal, even in the presence of moderately severe symptoms. Assessment of solid emptying by means of a radiolabel that tags the solid phase of the meal is a more sensitive test with a well -defi ned normal range. The proportion of radioisotope retained in the stomach at 2 and 4 hours distinguishes normal function from delayed gastric emptying with a sensitivity of 90% and a specifi city of 70% [71] . The importance of obtaining scans for 4 hours after a meal cannot be overemphasized. Because gastric emptying is slow initially, it is not accurate to extrapolate emptying from scans taken for a shorter duration. Another useful test for measuring solid phase gastric emptying utilizes a standardized meal with biscuit enriched with 13 C, a substrate containing the stable isotope. When metabolized, the proteins, carbohydrates and lipids of the S. platensis or the medium chain triglyceride octanoate give rise to respiratory CO 2 that is enriched in 13 C. Measurement of 13 CO 2 breath content (a refl ection of the amount of biscuit remaining in the stomach) by isotope ratio mass spectrometry allows an estimation of gastric emptying t 1/2 [72] . Further validation of this technique is necessary in patients with bacterial overgrowth and small bowel mucosal disease.
For patients with severe upper gastrointestinal symptoms, antropyloroduodenal manometry is a specialized technique that assesses pressure profi les in the stomach and small bowel and also guides management. Manometry may also reveal hypomotility of the gastric antrum and/or an intestinal neuropathy (Figures 46.6  & 46.7 ) . Patients with selective abnormalities of gastric function may be able to tolerate enteral feeding (delivered directly into the small bowel) whereas patients with a more generalized motility disorder may not.
Gastric accommodation in response to meal ingestion may be impaired in diabetes [73] . This may contribute to the gastrointestinal symptoms of nausea, bloating and early satiety. Imaging of the stomach wall using 99m Tc pertechnetate allows measurement of gastric volume after meal ingestion.
For patients with constipation, colonic transit, anorectal manometry and rectal balloon expulsion tests provide a useful start. Anorectal manometry and the rectal balloon expulsion test generally suffi ce to diagnose or exclude defecation disorders; magnetic resonance imaging (MRI) or barium proctography are only required in selected patients. Colonic transit is often delayed in patients with defecatory disorders. Therefore, in patients with slow colonic transit, slow transit constipation can only be diagnosed after excluding defecatory disorders. Intraluminal assessments of colonic phasic motility (by manometry) and tone (by barostat) often reveal other dysfunctions (e.g. impaired contractile responses to a meal and/or pharmacologic stimuli (e.g. bisacodyl or neostigmine) in patient with slow transit constipation. Colonic transit can be characterized by radiopaque markers, which, depending on the technique, takes 5 -7 days, or by scintigraphy, which takes 24 -48 hours. Both techniques are equally accurate for identifying slow or rapid colonic transit. overgrowth [74] . To reduce the potential impact of this confounding factor (i.e. rapid intestinal transit), a more restricted defi nition to diagnose small intestinal overgrowth may be preferable. An early hydrogen peak (20 ppm ), caused by small intestinal bacteria, may be seen at least 15 minutes before the later prolonged peak, which corresponds to the passage of the remaining lactulose into the colon. Even with more restricted defi nitions, the sensitivity and specifi city of the lactulose hydrogen breath test in detecting small bowel bacterial overgrowth have been reported to be only 68% and 44% and for the glucose breath test 62% and 83%, respectively [73] .
Management
The principles of management are to address fl uid and nutritional requirements, improve glycemic control and treat symptoms.
Small intestinal dysmotility may manifest as one or more of the following features: abnormal migrating motor complexes; failure to convert from fasting to post -prandial motor pattern and/or features of a vagal neuropathy such as excessive number of fasting migrating motor complexes or persistent post -prandial migrating motor complexes). Assessment of stool fat provides a useful differentiation point for diabetic diarrhea, as it indicates malabsorption as the pathophysiology leading to diarrhea. An upper endoscopy provides an opportunity to obtain duodenal aspirates for bacterial overgrowth and small bowel biopsy to exclude celiac disease. Lactose or glucose hydrogen breath tests rely on substrate metabolism by bacterial overgrowth in the small intestine with hydrogen release and breath excretion; however, studies have shown that the early peak is frequently caused by rapid delivery of the substrate to the colon with bacterial metabolism by normal colonic fl ora rather than small bowel bacterial Tests parasympathetic supply to bladder, not bowel is preferable to place jejunal feeding tubes directly into the jejunum either by endoscopy, or if necessary by laparoscopy or mini laparotomy, rather than via percutaneous endoscopic gastrostomy tubes. Such tubes allow restoration of normal nutritional status but they are not without adverse effects. There is no evidence to suggest that gastrectomy relieves symptoms or enhances quality of life. Patients with gastroparesis often have concomitant small intestinal denervation which is likely to cause persistent symptoms after gastrectomy [27, 77] . If the patient remains symptomatic, other prokinetic agents may be considered as adjuncts. In the USA, the only available medication is metoclopramide, a peripheral cholinergic and antidopaminergic agent. During acute administration, it initially enhances gastric emptying of liquids in patients with diabetic gastroparesis, but its symptomatic effi cacy is probably related to its central antiemetic effects. Its long -term use is restricted by a decline in effi cacy and by a troubling incidence of central nervous system side effects. Therefore, the authors prefer to prescribe a dose of 10 mg t.i.d., administered 30 minutes before meals, for a short duration; the higher dose is 20 mg t.i.d. A systematic review of trials concluded there was limited evidence to support the use of domperidone, which is another dopaminergic antagonist not approved for use in the USA [78] . Endoscopic injection of botulinum toxin into the pylorus was not effective in controlled studies primarily of patients with idiopathic gastroparesis [79, 80] .
Although the Food and Drug Administration (FDA) recognizes gastric electrical stimulation as a humanitarian use device for refractory gastroparesis, its use for this indication is controversial. While published data suggest that the device reduces
Gastroparesis and d yspepsia
While nutritional requirements and symptoms can be addressed to a variable extent in patients with mild and compensated gastroparesis, patients with severe gastroparesis often require hospitalization for one or more of the following measures: intravenous hydration and correction of metabolic derangements (ketoacidosis, uremia, hypo -/hyperglycemia), nasoenteric decompression, and/or enteral nutrition to manage vomiting and nutritional requirements [54] . Parenteral nutrition may become necessary in cases of malnutrition. Bezoars may be mechanically disrupted during endoscopy, followed by gastric decompression to drain residual non -digestible particles. Erythromycin at a dose of 3 mg/ kg body weight intravenously every 8 hours can accelerate gastric emptying [75, 76] . When oral intake is resumed, treatment with oral 250 mg erythromycin t.i.d. for 1 -2 weeks is worthwhile. Thereafter, the prokinetic effects of erythromycin are limited by tachyphylaxis. Anecdotal fi ndings suggest that erythromycin may be effective if courses are separated by a drug -free period (e.g. lasting 2 weeks). Hyperglycemia interferes with the prokinetic effect of intravenous erythromycin on gastric emptying in healthy subjects and patients with diabetes [34] . Because both liquids and homogenized solids are more readily emptied from the stomach than solids, liquid or blenderized food will be better tolerated. Frequent monitoring of blood glucose levels is essential during this phase.
For patients with severe gastroparesis who do not respond to the measures outlined above, it may be necessary to bypass the stomach with a jejunal feeding tube. This procedure should be preceded by a trial of nasojejunal feeding for a few days of with infusion rates of at least 60 mL iso -osmolar nutrient per hour. It healthy subjects and improves symptoms in functional constipation [89 -91] . While there are no studies in patients with diabetes and constipation, lubiprostone should be considered in patients who have not responded to osmotic agents.
vomiting frequency only when the device is on, data submitted to the FDA concluded that electrical stimulation reduced vomiting frequency to a similar extent with the device turned off or on, suggesting a placebo response [81, 82] . Moreover, the device is expensive and does not accelerate gastric emptying. Between 10 and 20% of patients have device -related complications.
Diabetic d iarrhea
Diabetic diarrhea is treated symptomatically with loperamide, preferably administered 30 minutes before meals, in the dose range of 2 -16 mg/day. Consumption of artifi cial sweeteners that contain the osmotically active sugar substitute sorbitol should be reduced. Second -line approaches are clonidine, 0.1 mg orally or by patch, in patients who do not experience signifi cant postural hypotension [83] . Amitriptyline, which has anticholinergic effects, may reduce intestinal cramping and transit. Octreotide (25 -50 μ g subcutaneously 5 -10 minutes before meals) delays small intestinal transit [84] and may also reduce secretory diarrhea associated with rapid intestinal transit [85] . While it has been suggested that octreotide reduces small bowel bacterial overgrowth in chronic intestinal pseudo -obstruction [86] , this study assessed for bacterial overgrowth by breath testing. Indeed, by delaying small intestinal transit, octreotide may predispose to bacterial overgrowth. Regulating stool consistency may also improve fecal continence. In addition, pelvic fl oor retraining with biofeedback therapy can improve rectal sensation, and enhance coordination between perception of rectal distention and contraction of the external anal sphincter [44] ; however, biofeedback therapy is less effective in patients with markedly reduced rectal sensation. A descending colostomy may be required and may improve the quality of life in patients with severe diarrhea associated with fecal incontinence.
Constipation
For patients without pelvic fl oor dysfunction, chronic constipation can be generally managed with pharmacologic agents such as osmotic and stimulant laxatives [87] . Pelvic fl oor retraining by biofeedback therapy is the cornerstone for managing defecatory disorders; laxatives are used as an adjunct to pelvic fl oor retraining [88] . Fiber supplementation, either with dietary supplementation or with fi ber products (e.g. psyllium 15 -18 g/day), should be considered in patients with inadequate fi ber intake. Of the osmotic laxatives, polyethylene glycol (up to 17 g in 8 ounces of water once or twice per day) is a widely used and safe over -thecounter agent. While lactulose is a poorly absorbed disaccharide, lactulose syrup contains small amounts of absorbable sugars and may increase hyperglycemia. Magnesium compounds are safe but patients with impaired renal function may develop magnesium retention. Bisacodyl or glycerin suppositories are useful rescue agents in patients who do not have a bowel movement for 2 days. If possible, suppositories should be administered 30 minutes after a meal to synergize pharmacologic therapy with the physiologic response to a meal. By activating chloride channels and inducing colonic secretion, lubiprostone accelerates colonic transit in
